Digital Diagnostics AG

  • Land: .

Nachricht vom 30.05.2020 | 03:47

After Scientific Breakthrough: Digid Seeks FDA Approval for Its Rapid Corona Antigen Test

DGAP-News: Digital Diagnostics AG / Key word(s): Miscellaneous
30.05.2020 / 03:47
The issuer is solely responsible for the content of this announcement.

Mainz, Germany--(Newsfile Corp. - May 29, 2020) - At the high-security laboratory of the Helmholtz Centre for Infection Research (HZI) in Braunschweig, Germany, the revolutionary Cantisense™ technology of the German health technology company Digital Diagnostics AG was used for the first time to successfully detect SARS-CoV-2 viruses in high measuring accuracy in test liquids.

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/7052/56911_119b98cb04e5d8c4_001.jpg

Figure 1: Point-of-care test kit: sensor hub, biosensor, mobile device

With digid's point-of-care solution, the measurement results are transmitted wirelessly from a sensor hub to a mobile device. By connecting to a secure analytics platform, the numerous sensor data can be augmented with further data and processed anonymously for research and diagnostic applications. (prototype/copyright: Digital Diagnostics AG)

To view an enhanced version of Figure 1, please visit:
https://orders.newsfilecorp.com/files/7052/56911_119b98cb04e5d8c4_001full.jpg

In contrast to PCR testing, the new test provides a clear electronic "YES" or "NO" information within a few minutes, saving precious time in the diagnosis. What's more, the Digid Cantisense™ SARS-CoV-2 Test directly detects the presence of the virus while other rapid tests only recognize antibodies.

Konstantin Kloppstech, CTO at Digital Diagnostics, says: "Recent test series at the HZI high-security laboratory have shown that SARS-CoV-2 viruses can be detected directly using our Cantisense technology and without the need for PCR or further sample processing. This is a scientific breakthrough. We have coated cantilevers with a capture layer of highly specific monoclonal antibodies, which can reliably bind SARS-CO-2 viruses in the test fluid."

Constantin von Gersdorff, CEO of Digital Diagnostics, said: "The next step will be to initiate clinical studies with patient samples. To this end, we have already established international collaborations with leading hospitals."​

With Digid's test kit, the measurement results are transmitted wirelessly from a sensor hub to a mobile device. By connecting to a secure analytics platform, the sensor data can be augmented with further data and processed anonymously for research and diagnostic applications.

Due to its measurement speed and the highly reliable results, the test is particularly suitable to support the containment of the current SARS-CoV-2 pandemic. The test offers the possibility of simple and rapid testing of patients and medical staff as an alternative to laboratory tests and enables reliable identification of infected persons within minutes. The possible areas of application therefore also include screening for access control at airports and railway stations, hospitals and specially protected areas (such as retirement homes) as well as for companies who want to ensure that their production runs smoothly and safely.

Digital Diagnostics has applied for approval of the Digid Cantisense™ SARS-CoV-2 Test by the US Food and Drug Administration (FDA). Digid aims to provide millions of units by July 2020. A further scaling of capacities is planned in the short term. The experts at Digital Diagnostics are also working at full speed to further develop the technology and to adapt the point-of-care testing procedure for use by consumers at home.​

Press contact
Thomas Huber
semanticom GmbH
+49 30 275 80 81 11
digid-pr@semanticom.eu

Related Images

point-of-care-test-kit-sensor-hub.jpg
Point-of-care test kit: sensor hub, biosensor, mobile device
With digid's point-of-care solution, the measurement results are transmitted wirelessly from a sensor hub to a mobile device. By connecting to a secure analytics platform, the numerous sensor data can be augmented with further data and processed anonymously for research and diagnostic applications. (prototype/copyright: Digital Diagnostics AG)

Related Links

https://digid.com/en/

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/56911

Click on, or paste the following link into your web browser,to view the associated documents http://www.newsfilecorp.com/release/56911
News Source: Newsfile


30.05.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

Interview im Fokus

„Im europäischen Spitzenfeld der Private-Equity-Liga“

Die Münchner Private-Equity-Gesellschaft Mutares (ISIN: DE000A2NB650) ist mit bereits fünf Akquisitionen in 2020 erneut mit einem hohen Wachstumstempo unterwegs. Im Exklusivinterview mit Financial.de verraten die Vorstände Robin Laik (CEO) und Johannes Laumann (CIO), wie man sich bei den jüngsten Deals gegen die Konkurrenz durchgesetzt hat, wie man einen Return auf das eingesetzte Kapital von 7 bis 10 erreichen will und warum sich Mutares-Aktionäre auch für 2020 auf eine attraktive Dividende freuen dürfen.

Event im Fokus

Fachkonferenz Beteiligungsgesellschaften, 15.07.2020

Fachkonferenz Consumer / Leisure, 16.07.2020

Die Konferenzen finden aufgrund der aktuellen Situation nicht in den Räumen der Börse München statt, sondern als Online-Konferenz.

GBC-Fokusbox

Anleihe der German Real Estate Capital S.A. stark überdurchschnittlich attraktiv

Die Anleihe der German Real Estate Capital S.A. weist aktuell eine Effektivverzinsung von ca. 14 % auf. Da es sich hier quasi um eine Immobilien-Anleihe handelt, ist das Anleiherisiko überschaubar. Insgesamt verfügt die German Real Estate-Gruppe über 6 Objekte, 24 Bestands- und 22 Handelsobjekte, womit eine Kombination aus stetigen Einnahmen und attraktiven Entwicklerrenditen erreicht wird. Wir stufen die Anleihe als stark überdurchschnittlich attraktiv ein.

News im Fokus

HeidelbergCement AG: Vorläufiges Ergebnis von HeidelbergCement im zweiten Quartal 2020 über Markterwartungen

14. Juli 2020, 16:38

Aktueller Webcast

TeamViewer AG

Webcast TeamViewer acquires Ubimax

15. Juli 2020

Aktuelle Research-Studie

Original-Research: GBC Insider Focus Index (von GBC AG): GBC Insider Focus Index

15. Juli 2020